Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-03-09
Target enrollment:
Participant gender:
Summary
This is a phase II trial to explore the efficacy and safety of weekly utidelone in
HER2-negative inoperable locally advanced or metastatic breast cancer.